MindMed announces that interim CEO Robert Barrow has now been named the permanent CEO, and added as a Director.

Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.

Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.

MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.

Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.

MINDCURE’s iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that’s only the beginning of its potential.

Novamind’s new Salt Lake City clinic will specialize in treating substance abuse disorders.

GH Research reports its Q3 for 2021 and announces VERY successful results from its Phase 2a trial for Treatment Resistant Depression (TRD).

Mydecine files a detailed patent application covering “multiple families of psilocin analogs.”

GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.